Research & Development
Access To Healthcare
Who We Are
Annual Report 2015
Share Data & Analysis
Working at Novartis
Awards & Recognition
Compensation & Benefits
Careers in Research
Six-year pivotal study data reinforce the superiority of Tasigna® over
® in newly-diagnosed patients with Ph+ CML
Fewer patients on Tasigna vs.
had their leukemia progress to advanced stage, a key goal of treatment ... confirm the favorable risk/benefit profile of Tasigna vs.
in newly-diagnosed CML patients Basel, December 8, 2014 - ... the superiority of Tasigna ® (nilotinib) compared to
® (imatinib)[*] at achieving higher rates of early, deep and ...
Patents and Medical Progress
... patents to development of medicines; information about the
patent case in India. To continue to provide patients with safe ... patents, indian patent law, intellectual property, ip,
, gleevec, access to medicine, ethics, responsibility, oncology, cml, ...
Oncology Patient Assistance Programs
... that have challenging healthcare environments. The
International Patient Assistance Program In 2002, Novartis Oncology introduced the
International Patient Assistance Program (GIPAP TM ). This program, ...
... change (cc) 2015 franchise
.jpg 4,658 5% Oncology ...
Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML
... MR4.0 rate in all treated patients with <=3 months of prior
treatment (n=1,052) was 38.4% at 18 months and 40.4% at 24 months. As ... MR4.5, and a reduced risk of progression compared to
. Consistent with prior studies, ENEST1st demonstrated the importance ...
Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014
... are reminded of how far we've come since the unprecedented
data unveiled exactly 15 years ago - a turning point in precision ... , www.afinitor.com , www.tasigna.com , www.
.com and www.exjade.com . Because CTL019, BKM120, LGH447, ...
Water and Micro-pollutants
... Entresto Exelon Exforge Galvus Gilenia
/Gleevec Odomzo Rasilez Tasigna Zykadia Various ...
Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research
... designed to inhibit BCR-ABL. ABL001 is different from
® (imatinib)* and Tasigna ® (nilotinib) as it binds to a unique ... or regarding potential new indications or labeling for
, Tasigna, Jakavi or Farydak, or regarding potential future revenues from ...
Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting
... Tasigna ® both in front-line and second-line following
® * First genomic analysis and 3-year efficacy/safety ... (trametinib) combination therapy, Tasigna (nilotinib),
(imatinib), Femara (letrozole), everolimus, Tykerb (lapatinib), Zykadia ...
Novartis publishes updated 2015 segment financials reflecting new division structure
... decline (mid-single digit growth excluding Gleevec ® /
® generic impact) Alcon: low single digit growth Sandoz: ... to USD 2.2 billion in 2015. Excluding Gleevec ® /
® generic impact, we would expect Group net sales to grow mid-single ...
© 2016 Novartis AG
This site is intended for a global audience.